Status and phase
Conditions
Treatments
About
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to evaluate the combination of Pembrolizumab + sEphB4-HSA in the population of patients with previously untreated advanced (metastatic or recurrent) urothelial carcinoma who are chemotherapy ineligible or who refuse chemotherapy.
Full description
The combination of Pembrolizumab + sEphB4-HSA will be given through an intravenous infusion (into a vein). Each cycle of sEphB4-HSA will be given at Day 1, 8, and 15 of each 3 week cycle. Each cycle of Pembrolizumab will be given at Day 1 of each 3 week cycle.
Participants may continue on study protocol as long as they continue to respond and remains clinically stable on study medication.
Patients may come off treatment for the following reasons:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
In addition, we request an OPTIONAL collection of any surgical specimens obtained per standard of care during the study. For instance, specimens from metastasectomy while patient is undergoing therapy on this study.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
38 participants in 1 patient group
Loading...
Central trial contact
Jon Cogan, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal